Technical Analysis for MVRBF - Medivir Ser B Sek5

Grade Last Price % Change Price Change
grade D 2.2 10.00% 0.2000
MVRBF closed up 10.0 percent on Friday, September 20, 2019, on 17 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
See historical MVRBF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish 10.00%
Narrow Range Bar Range Contraction 10.00%
Gapped Up Strength 10.00%
New 52 Week Closing Low Bearish 29.41%
Stochastic Buy Signal Bullish 29.41%
Hot IPO Pullback Bullish Swing Setup 29.41%
Older signals for MVRBF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Europe, the Nordic region, the United States, and the rest of the world. The company's products portfolio includes Remetinostat, which has completed Phase II clinical study for use in the treatment of cutaneous T-cell lymphoma; Birinapant in combination with Keytruda that is in phase I/II study for treating solid tumors; and MIV-711, which is in Phase IIa study that is used for the treatment of osteoarthritis, as well as MIV-818, a preclinical stage nucleoside pro-drug for treating patients with advanced liver cancers. Its products also include Xerclear for use in the treatment of labial herpes in Europe and the rest of the world; MIV-802, a pan-genotypic nucleotide-based inhibitor of the hepatitis C virus NS5B polymerase, which is in preclinical development in Greater China; and Simeprevir/OLYSIO, an antiviral combination treatment regimen for chronic genotype 1 and 4 hepatitis C infection in adult patients with liver disease, including cirrhosis. Medivir AB (publ) was founded in 1988 and is headquartered in Huddinge, Sweden.
Chemistry Medicine RTT Pharmaceuticals Solid Tumors Osteoarthritis Organic Chemistry Healthcare Associated Infections Cyclopropanes Hepatitis C Hepatocellular Carcinoma Infectious Causes Of Cancer Liver Disease Cirrhosis Cutaneous T Cell Lymphoma Sulfonamides Treatment Of Osteoarthritis Treatment Of Cutaneous T Cell Lymphoma

Is MVRBF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 8.5
52 Week Low 1.7
Average Volume 1,720
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 3.8136
10-Day Moving Average 2.3832
Average True Range 0.4774
ADX 0.0
+DI 21.8540
-DI 78.1460
Chandelier Exit (Long, 3 ATRs ) 7.0678
Chandelier Exit (Short, 3 ATRs ) 3.1322
Upper Bollinger Band 7.4341
Lower Bollinger Band 0.1931
Percent B (%b) 0.28
BandWidth 189.8731
MACD Line -1.1823
MACD Signal Line -0.8455
MACD Histogram -0.3368
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.2000
Resistance 3 (R3) 2.2000 2.2000 2.2000
Resistance 2 (R2) 2.2000 2.2000 2.2000 2.2000
Resistance 1 (R1) 2.2000 2.2000 2.2000 2.2000 2.2000
Pivot Point 2.2000 2.2000 2.2000 2.2000 2.2000
Support 1 (S1) 2.2000 2.2000 2.2000 2.2000 2.2000
Support 2 (S2) 2.2000 2.2000 2.2000 2.2000
Support 3 (S3) 2.2000 2.2000 2.2000
Support 4 (S4) 2.2000